-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677

Benzinga·08/06/2026 17:57:27
Listen to the news
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $704 to $677.